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Statement of Translational Relevance: 
 
 Intra-patient molecular heterogeneity in advanced metastatic castration resistant has been 
underexplored. Using whole-genome sequencing of 21 tumors from 10 patients, we show, 
in agreement with previous studies, an overall limited genomic heterogeneity in putative 
cancer drivers. However, private aberrations in putative drivers were identified. We also 
uncovered intra-patient heterogeneity in aberrations involving the RB1 gene and proceeded 
to study this in an independent cohort of metastatic castration-resistant prostate cancers 
(mCRPCs). We show RB1 copy number losses are common (~56%) in tumors with previous 
exposure to taxanes and anti-androgens. We also identify genomic rearrangements as a 
common putative second hit. Finally, RB1 protein expression was heterogeneous in ~28% of 
tumors, which has implications for ongoing trials of CDK4/6 inhibitors, as absence of 
functional RB1 is a negative predictive biomarker of response to these agents.  
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ABSTRACT (229 words)  
Purpose: Metastatic castration resistant prostate cancer (mCRPC) is a lethal but clinically 
heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic 
treatments. Intra-patient genomic heterogeneity could be a contributing factor to this 
clinical heterogeneity. Here we used whole-genome sequencing (WGS) to investigate 
genomic heterogeneity in 21 previously treated CRPC metastases from 10 patients to 
investigate intra-patient molecular heterogeneity (IPMH).  
Experimental Design: WGS was performed on topographically separate metastases from 
patients with advanced metastatic prostate cancer (PCa). IPMH of the RB1 gene was 
identified and further evaluated by fluorescent in situ (FISH) and immunohistochemistry 
(IHC) assays. 
Results: WGS identified limited IPMH for putative driver events. However, heterogeneous 
genomic aberrations of RB1 were detected. We confirmed the presence of these RB1 
somatic copy number aberrations (SCNA), initially identified by WG, with FISH, and 
identified novel structural variants (SV) involving RB1 in 6 samples from three of these ten 
patients (30%; 3/10). WGS uncovered a novel deleterious RB1 structural lesion constituted 
of an intra-genic tandem duplication involving multiple exons and associating with protein 
loss. Using RB1 IHC in a large series of mCRPC biopsies, we identified heterogeneous 
expression in ~28% of mCRPCs.  
Conclusion: mCRPCs have a high prevalence of RB1 genomic aberrations, with structural 
variants, including rearrangements, being common. Intra-patient genomic and expression 
heterogeneity favor RB1 aberrations as late, sub-clonal events that increase in prevalence 
due to treatment selective pressures.  
  
Cancer Research. 
on November 13, 2018. © 2018 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 26, 2018; DOI: 10.1158/1078-0432.CCR-18-2068 
 5 
Introduction 
 
Prostate cancer (PCa) is among the most frequently diagnosed malignancies worldwide (1). 
However, only about a quarter of all new cases will lead to cancer-specific death, 
highlighting the clinical heterogeneity of these tumors (1-3). Several large scale genomic 
studies of cohorts of primary, hormone-naïve and metastatic, castration resistant prostate 
cancers (mCRPC) have been performed suggesting both intra- and inter-patient molecular 
heterogeneity (4-11). Although multi-focality and genomic heterogeneity are well-known 
features of primary PCa (12-14), the level of intra patient molecular heterogeneity (IPMH) in 
mCRPCs is less well established. Samples of late stage disease are rarely acquired, with 
autopsy studies being expensive and logistically difficult, and few reports on IPMH in 
mCRPCs are available. 
 
Two studies have investigated the extent of IPMH in mCRPC patients. In a comprehensive 
molecular study using array comparative genomic hybridisation (aCGH), whole exome 
sequencing, and transcriptional profiling, Kumar et al reported that most presumptive 
driving genomic events and actionable targets are either present as common roots or 
“result from convergent evolution conferred by therapeutic pressures” (15). Further 
supporting this phenomenon of divergent genomics with convergent phenotypes, a WGS 
study of multiple metastases from 10 autopsied patients identified multiple separate 
endocrine treatment resistance mechanisms arising independently and subclonally within 
individual patients (16). Crucially, although both studies report some heterogeneity for 
known oncogenic drivers, neither followed up in dissecting gene-specific intra-patient 
heterogeneity using independent cohorts. Such efforts could shed light on the hierarchy of 
genomic events in PCa progression.    
 
The goal of this work was to identify recurrent intra-patient molecular diversity. We 
conducted WGS at >100X median coverage of 21 mCRPCs from 10 consecutive patients with 
>1 biopsiable non-bone metastases between 01/01/2013 to 31/12/2014. Our analyses, 
focused on 1,392 cancer-related genes, revealed intra-patient heterogeneity for the 
Retinoblastoma-Associated Protein (RB1), a tumor suppressor that inhibits pro-oncogenic 
E2F1 mediated transcription in its hypophosphorylated state (17). In a study of 500 
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metastatic samples of 20 different tumor types, including 93 mCRPCs, RB1 was shown to be 
genomically aberrant in 13.6% of the cases, this being among the most common 
deleteriously aberrant genes in metastatic disease overall (18). Critically, aberrations of RB1 
are commoner in mCRPC, indicating that these are either present at onset in clinically 
aggressive primary tumors or are acquired late in the natural history of prostatic 
malignancies.   
 
We then employed fluorescent in situ hybridisation (FISH) and immunohistochemistry (IHC) 
to further study RB1 loss and show that RB1 genomic aberrations are common in clinically 
aggressive primary PCa, becoming commoner in mCRPC regardless of histology. We 
demonstrate that structural variants involving RB1 are frequent in mCRPCs and may be a 
common putative second hit. Finally, we show that heterogeneous RB1 protein loss is 
common, favoring RB1 depletion as a late event in the natural history of PCa. 
 
Methods 
 
Population and Tissue Samples 
 
Patients gave their written informed consent and were enrolled to protocols approved by 
the Royal Marsden NHS Foundation Trust Hospital (London, UK) ethics review committee 
(Reference no. 04/Q0801/60). Demographics and clinical data were retrospectively 
collected from electronic hospital records. WGS data was generated from 21 samples from 
10 consecutive patients with >1 accessible non-bone metastases acquired between 
01/01/2013 and 31/12/2014. Additionally, FISH and IHC data were generated from 
randomly selected metastatic samples collected between 01/01/2013 and 31/12/2016. In 
this second cohort, metastatic sites included lymph node, bone, viscera, and soft tissues. 
Minimum tissue quality criteria required the presence of at least 50 well-preserved cancer 
cells. Patient matched hormone-sensitive tumors for a subset of cases were studied. 
 
Whole Genome Sequencing 
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For each of the 21 metastases, tumor DNA was extracted from seven 10m thick frozen 
sections after confirmation of tumor cell presence on a 4m thick H&E stained slide. 
Germline DNA was extracted from saliva. The QIAmp DNA Mini Kit (#51304; Qiagen, 
Hilden, Germany) was used for DNA isolation from both fresh/frozen sections and buccal 
swabs. Library preparation was performed using the TruSeq Nano DNA Library Prep kit. 
Sequencing was performed using the Illumina HiSeq 2000 System. Tumor and matched 
germline DNA samples were profiled with a WGS protocol. Paired-end sequencing reads 
were aligned to the human reference genome (GRCh37/hg19) using Illumina Isaac Genome 
Alignment Software (19) embedded in Illumina pipeline version v2.0.1. Genome Analysis 
Toolkit (GATK v2.6) (20) best practices for variant calling that included marking of duplicate 
reads, recalibration of base quality scores and local realignment were adopted for all 
aligned samples. Germline-tumor pair consistency was tested using the SNP panel 
identification assay (SPIA v1.1.0) (21). To identify and characterize somatic single-nucleotide 
variants (SNVs) in exons, the MuTect v1.1.6 (22) tool was used. To reduce false positives, 
calls were refined and confirmed using an ad-hoc pileup approach using ASEQ v.1.1.8 (23) 
and adopting stringent filtering quality criteria. Finally, each retained SNV was annotated 
with genomic features and effect/impact prediction using the SnpEff v4.1a tool (24). For 
each tumor and matched normal WGS sample, the algorithm BreakDancer v1.2 (25) was run 
with default parameters to detect genomic SVs including intra- and inter-chromosomal 
translocations. The raw output of BreakDancer was filtered using stringent criteria based on 
quality score and minimum number of reads supporting the SV. Additionally, an ad-hoc WES 
based computational strategy was developed to support evidence of significant enrichment 
in the coverage of exons involved in tandem duplications detected in the RB1 gene. Briefly, 
the mean coverage in each RB1 exon was computed separately in tumor and normal 
samples and normalized to the total coverage of all RB1 exons (N=27). Then, the ratio 
between tumor and matched normal normalized mean coverages was computed for each 
RB1 exon. Finally, the method computed the median ratio grouping exons 1 to 6 (Rupstream), 7 
to 17 (Rtandem duplication), and 8 to 27 (Rdownstream). Tandem duplication events were compatible 
with high ratios Rtandem duplication / Rupstream and Rtandem duplication / Rdownstream. Estimation of 
genomic segments and SCNA was obtained using BICseq v1.1.11 algorithm (26). Segmented 
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data were used in combination with CLONET v2.0.0 (27) to estimate ploidy and purity for 
each tumor sample, and further to determine allele-specific copy number.  
 
Cell lines 
 
22Rv1 (ATCC®CRL-2505), a PCa- and MD-MBA-468 (ATCC®HTB-132), a triple-negative breast 
cancer- cell lines were purchased from ATCC and cultured according to the manufacturer’s 
protocol. Cell pellets were fixed in 10% neutral buffered formalin overnight at 4oC. After 
dehydration in ethanol, at 70% (10 minutes), 80% (10 minutes), 90% (10 minutes), and 100% 
(3x10 minutes), lipid removal and diaphonisation were performed with xylene (3x15 
minutes).  
 
Antibody Validation, Immunohistochemistry, and Scoring Methods 
 
Antibody target specificity validation was confirmed by performing Western Blots of cell 
lysates as previously described (28). For immunohistochemistry (IHC), FFPE samples were 
cut at 4μm thick sections onto glass slides and dewaxed with xylene. Antigen unmasking 
was performed by heating slides in a pH6 citrate buffer solution for 18-minutes using a 
microwave at 900W. Staining was performed with conventional diaminobenzidine method 
using the i6000 autostainer (Biogenex; Fremont – CA, USA). The Dako-Envision kit (Agilent-
Dako, Santa Clara – CA, USA) was used for reaction visualisation. A mouse monoclonal anti-
RB1 antibody targeting amino acids 332-344 (Clone G3-245, BD Biosciences, Franklin Lakes – 
NJ, USA) diluted 1:50 was used. Endogenous peroxide was blocked using a 3% H2O2 solution; 
non-specific staining was blocked using Dako protein block serum-free X0909, and the 
diluted primary antibody was incubated on tissue samples for 1 hour. We used MDA-MB-
468, a triple-negative breast cancer cell line with biallelic deletion of the RB1 locus 
(c.265_2787del2523) as negative control, and 22RV1, an AR positive PCa cell line with 
genomically intact RB1 as a positive control. Absence of IHC AR staining (Clone AR441, 
Agilent-Dako, Santa Clara – CA, USA) was used as a surrogate marker of neuroendocrince 
prostate cancer (NEPC). This validated anti-AR antibody assay was performed as previously 
described (28). An H-Score determined by the formula: (% of negative)x0 + (% of weak 
positivity)x1 + (% of moderate positivity)x2 + (% of strong positivity)x3, yielding a result 
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between 0 and 300, was used for RB1 protein expression semi-quantitative analyses. 
Samples with any proportion of tumor cells lacking RB1 staining with good internal controls, 
i.e. RB1 positive endothelial or stromal cells, were interpreted as heterogeneous, and 
positivity was considered of weak intensity to reflect an H-Score of <100. AR was 
dichotomously scored as either positive or negative, with the cut-off for positivity being 
expression >0.  
 
Fluorescent in situ Hybridisation (FISH) 
 
Fluorescent in situ hybridisation (FISH) was performed as previously described (29). We 
optimised a dual colour FISH assay using two commercially available FISH probes: 1) a ~202 
Kb probe directly labelled with Spectrum Orange targeting the 13q14 locus spanning RB1, 
and 2) a ~612 Kb probe directly labelled with Spectrum Green targeting the subtelomeric 
13q34 locus (Abbot Laboratories, Lake Bluff, IL-USA). A sub-telomeric control probe was 
selected because homologies in centromeric alpha satellites between chromosomes 13 and 
17 could compromise gene copy number enumeration (30). We defined copy number gains 
(CNG) as a ratio of RB1 signals/nuclei ratio of >2; copy number neutral (CNN) as a ratio of 
RB1 signals/nuclei ratio of <2 and ≥1.7; shallow deletions (SD), i.e. mostly heterozygously 
deleted, as a ratio of RB1 signals/nuclei <1.7 and ≥1, and deep deletions (DD), i.e. at least 
focally homozygously deleted, as a ratio of <1. At least 50 intact non-overlapping nuclei 
were counted per sample and the number of cells with >2, 2, 1, or 0 signals was recorded 
for both probes. The controls used for RB1 IHC were the same as those used for FISH, 
namely MDA-MB-468 as negative and 22RV1 as positive controls respectively. 
Figures and Statistical Analysis 
Figures were generated using R version 3.3.2 and GraphPad Prism v7. Statistical tests were 
performed using GraphPad Prism v7 and STATA v15. 
Ethics Statement 
The work herein presented was conducted to Good Clinical Practice standards and in 
accordance to the Declaration of Helsinki.   
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Results 
Clinical features of the patients selected for WGS 
Patients in this study had clinically aggressive disease, the majority being stage IV at 
diagnosis; their clinical data are summarised in Table 1. Median age of the WGS cohort was 
58.8 years (IQR: 50.84-61.4). Gleason scores were available for 9 patients, 4 having scores of 
≤7 and 5 of >7. Two patients had local treatment with radical prostatectomy followed by 
salvage radiotherapy. Another two patients had radical radiotherapy. Eight of the ten 
patients had locally advanced disease, i.e. ≥T3, with six having M1 disease, at diagnosis. 
Median time on androgen deprivation therapy was 14.99 months (IQR: 6.95-49.15 months). 
A summary of all patient treatments and best clinical responses are available in 
Supplementary Figure 1.  Twenty-one (21) mCRPC biopsies were collected from these 10 
patients; 2 samples per patient except one subject from whom we had three separate 
nodules from a penectomy specimen.  In 7 patients, these mCRPC samples came from 
enlarged, topographically distant, lymph nodes; in two men, liver mCRPC biopsies and 
lymph-node biopsies were available; in one subject liver and muscle mCRPC biopsies were 
acquired. No complications occurred during tumor sampling.  All biopsies included a fresh 
frozen sample for genomic sequencing studies and a formalin-fixed, paraffin embedded, 
sample to confirm tumor histology and for IHC studies. Fresh-frozen samples were cut at 
4m and rapidly stained with H&E to confirm tumor content. Nineteen of 21 samples had 
>50% tumor content, with the remaining two cases having ~10% and ~25%.  
 
Bulk-tissue WGS shows limited Intra-patient genomic heterogeneity  
We obtained WGS data from these 21 tumor samples from 10 patients; 21 tumor and 10 
matched germline DNA samples were profiled at a median sequencing coverage depth of 
109X and 37X, respectively. Genomic profiles of tumor samples were defined from WGS 
data by applying an ad hoc computational workflow. CLONET estimated tumor ploidy, purity 
and corrected SCNA in all but 2 tumor samples that showed low quality data. Overall, tumor 
cellularity was high (median=74%, min=38%, max=94%) and polyploidy (genomes with more 
than 2 paired sets of chromosomes) was detected in all tumor samples. 
 
Our initial approach focused on genes of taxonomical relevance, i.e. clonal, mutually 
exclusive events that define genomic subtypes (31) and previously reported by the SU2C 
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International team CRPC study (32). We identified ETS rearrangements in 13 samples from 6 
patients; in 11 of these samples from 5 patients, ERG was the ETS partner involved. WGS 
segmented data indicated the presence of an interstitial deletion spanning approximately 
3Mb between ERG and TMPRSS2 in 7 samples from 3 patients (V4074, V5162 and V4038). 
Breakpoints of this deletion were consistent among samples within the same patient. In 2 
samples from one patient (V4002), we identified a previously unreported fusion between 
ETV1 and MIOS. ETS rearrangement status were identical in different samples from an 
individual patient. The remaining 4 ETS rearrangement negative cases did not have clonal 
somatic mutations in SPOP, IDH1, or FOXA1, subgroup-defining genomic lesions described 
by the TCGA consortium (4).  
 
The landscape of identified coding variants of interest through this WGS are summarised in 
Figure 1. First, we quantified the total number of somatic single nucleotide variants (SNVs) 
in coding regions for each tumor sample and found a median number of 173 (min=127, 
max=494) variants. When the analysis was stratified by functional annotation, the median 
number of non-synonymous SNVs was 43 (min=27, max=127). The two tumors harbouring 
the highest number of SNVs, with 494 and 456 bases mutated (127/494 and 123/456 being 
non-synonymous SNVs), were from the same patient and presented a deleterious mismatch 
repair gene aberration (i.e. missense variant p.Ile185Val in MLH3). Second, we estimated 
for each sample the fraction of the genome that was impacted by a SCNA, here defined as 
copy number altered fraction (CNAF). The median CNAF across tumor samples was 0.83 
(min=0.35, max=0.94). These fractions were significantly higher than those reported by 
Hieronymus et al. in aCGH and low-pass WGS studies in hormone sensitive primary and 
metastatic prostate cancers, with CNAF of 0.04-0.05 and 0.32 respectively (33). Our data 
indicate that CNAF increases significantly in later stage mCRPC, suggesting that increased 
aneuploidy favours cell fitness and treatment resistance. To quantify the somatic CN 
similarities among metastatic sites from the same patient, we measured the correlation 
between log2 ratios in a set of 1,392 cancer related genes. Results based on log2 ratios of 
these genes indicated overall strong correlations with a median of 0.85 (min=0.53, 
max=0.95). We also focused on a subset of genes (N=32), reported in Figure 1 and 
selected based on their relevance to prostate carcinogenesis and key roles in important 
molecular pathways. The fraction of these genes with concordant copy number status 
across metastases from the same patient was on average 0.93 (median=0.95, min=0.75, 
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max=1). Overall, our somatic SNVs and CN analyses to assess intra-patient heterogeneity, 
confirmed low level diversity at a bulk tumor level as previously reported (15). 
 
However, genomic heterogeneity was identified in some patients. Aberrations in the WNT 
signalling pathway were seen as private events in two metastases from two distinct 
patients; the first showing a missense point mutation causing the protein change Ser680Arg 
in CTNNB1, with the latter showing a missense variant in APC (protein change Gly108Val). 
Amplification of AURKA, a serine-threonine kinase with key roles in centrosome maturation 
and spindle assembly (34), was seen in one of two samples from a single patient (V4038). 
Finally, in two patients (20%; 2/10), heterogeneous somatic genomic aberrations of RB1 
were identified between different metastases (Figure 1). In the first patient (V5128), one 
metastatic site had copy number neutral loss-of-heterozygosity with the other site having 
heterozygous loss. A second patient (V5033) had heterozygous loss in both metastases, but 
an additional single base substitution causing premature protein truncation at Glu204 in 
only one of them. Importantly, CLONET based tumor purity estimations of these samples 
were high (94%, 74% and 85%, 84%).    
  
RB1 Copy Number Enumeration by FISH and Protein Expression in mCRPC  
Given the observed intra-patient heterogeneity of RB1 loss in mCRPC, and the fact that 
these aberrations were more common than anticipated in mCRPC samples, we decided to 
further investigate RB1 loss by orthogonal assays pursuing RB1 FISH and RB1 IHC. We 
hypothesised that the presence of RB1 deletions in mCRPC from patients with matched, 
previously copy number normal, HSPC samples, as well as the presence of heterogeneous 
IHC staining in mCRPC biopsies would both favour disruptions of RB1 as late, sub-clonal, 
molecular events. These would have therapeutic relevance since RB1 loss-of-function is a 
putative predictive biomarker of resistance to CDK4/6 inhibitors (35), which have anti-tumor 
activity in ER+/HER2- breast cancer (36, 37), and are being evaluated in clinical trials of 
mCRPC (NCT02905318). The validation of RB1 FISH and IHC assays is summarised in 
Supplementary Figure 2. The MDA-MB-468 cell line had complete absence of IHC staining 
with rare cells having a single RB1 FISH signal, resulting in an RB1 signal to nuclei ratio 
(RB1s/Nuc) of 0.43 in 100 nuclei counted. The 22RV1 cell line had diffuse RB1 positivity on 
IHC and an RB1s/Nuc ratio of 2.03 in 100 nuclei counted. To validate copy number analyses 
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determined by sequencing and to query RB1 heterogeneity at the protein level, we analysed 
the 21 samples from 10 patients in the WGS cohort using RB1 IHC and FISH. FISH results 
were successfully acquired from 20 of 21 samples, with 19 of these also having RB1 copy 
number determined by WGS; FISH copy number analyses were consistent with WGS 
estimates in 16 samples (84%). All seven cases identified as hemizygously deleted for RB1 by 
WGS also had RB1 signal/Nucleus ratios of <1.7 by FISH enumeration; which validated our 
cut-off to define RB1 loss. Interestingly, one case was considered RB1 wild-type (WT) by 
WGS but had an RB1/Nucleus FISH ratio of 1.01, whereas two cases had ratios >2 but were 
reported WT by WGS. These discrepancies may have resulted from stromal contamination 
or pseudo-normalisation of genomic data in polyploid tumors. A comparison between RB1 
copy number evaluation by WGS and FISH, RB1 IHC and histological tumor type is presented 
in Supplementary Table 1.  
 
Structural variants of RB1: a putative mechanism of RB1 inactivation 
The identification of four mCRPCs with complete absence of RB1 expression without a 
significant proportion of cells showing genomic copy loss led us to hypothesise that other 
genomic events could account for a presumptive inactivation mechanism. Exploiting the 
WGS data we identified four distinct putative SVs involving RB1 in 6 metastases 
(6/21;28.57%) from 3 patients (3/10; 30%); 5 out of these 6 mCRPC biopsies (83.33%) had 
complete protein loss by IHC. Three of the four SVs were inter-chromosomal translocations 
and one was an intra-chromosomal tandem duplication. In two of these patients, these SVs 
were shared by multiple metastatic samples (S115, S116, S117 in patient V4074; and S363, 
S364 in patient V5191; all of these samples were IHC negative). In the third patient (V4038), 
a single sample presented with two distinct RB1 SVs but preserved IHC expression. 
 
In three samples with ADC histology from patient V4074, our computational analysis 
revealed RB1 copy number neutral LOH profile. Concomitantly, an increment in the number 
of sequencing reads spanning exons from 7 to 17 suggested an intragenic tandem 
duplication of the genomic segment containing exons 7-17. Using matched RNAseq data, we 
were able to validate the abnormal transcript generated by this intra-genic tandem 
duplication that would impair protein translation. Next, we first queried whole exome 
sequencing data from the same patient and verified the capability to detect the genomic 
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event by such a strategy, and next queried a large set of individuals (11) for the same event 
(N=149) (Figure 2). Although this specific RB1 structural event associating with full protein 
loss does not appear to be frequent, it evidences the importance of appropriate assay 
design to accurately query RB1 status for patient management. 
 
RB1 deletions are frequent in clinically aggressive HSPC and more common in mCRPC 
To further evaluate RB1 loss heterogeneity in lethal PCa we generated FISH data for RB1 
copy number analysis from 70 samples from 41 patients (including the 19 samples with WGS 
copy number data available). Importantly, the set included 20 HSPC and 50 CRPC biopsy 
samples, including 20 matched, same-patient HSPC-CRPC pairs (Figure 3A). Of the 20 HSPC 
samples, 35% (7/20) had at least shallow RB1 deletions, i.e. a gene signal/nuclei ratio <1.7, 
compared with 65% (13/20) of the matched, same patient, CRPC samples. Of the 13 HSPC 
samples with ratios ≥1.7 prior to any systemic therapy, 7 had matching CRPC samples with 
ratios <1.7, whereas 6 retained a ratio ≥1.7. Of the 7 HSPC samples with ratios <1.7 at 
diagnosis, only one matched CRPC sample had a ratio ≥1.7. Our data indicate an enrichment 
for RB1 deletions in clinically aggressive HSPCs, in line with a previous study on non-indolent 
PCa (38). More importantly, however, we also show RB1 deletions evolving in matched 
mCRPC from previously copy number neutral HSPCs.  
 
Deletions of RB1 in mCRPCs  
Overall, of the 50 mCRPC samples with FISH data, 43 were adenocarcinomas, 6 were NEPCs 
(cohort was enriched for NEPC), and 1 had mixed histology with predominantly (~95%) NEPC 
phenotype. An XY plot showing ratio between RB1/nuclei versus IHC H-Score and 
histological type notation is seen in Figure 3B. Copy number estimation of RB1 by FISH 
revealed a high degree of heterogeneity, with most tumors showing a subset of RB1 deleted 
cells larger than could be attributed by artefactual nuclear truncation, i.e. tangential 
sectioning of nuclei. Only twelve (24%; 12/50) mCRPCs were copy number neutral for both 
RB1 and reference probe. RB1 deletions, shallow or deep, were evident by FISH in 56% 
(28/50) of the mCRPC samples; shallow deletions were noted in 10 samples and deep 
deletions in 18 samples. The reference probe was not helpful for RB1 copy number 
enumeration as it was detected in various combinations being detected to be lost, neutral, 
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or gained independently of RB1 status, indicating frequent structural aberrations involving 
the 13q34 locus. 
 
Relationship of RB1 FISH enumeration and RB1 protein expression by IHC  
Twenty-two of 43 ADCs (22/43; 51.16%) had diffusely RB1 IHC positivity (IHCPos) (Figure 3B); 
RB1/nuclei FISH ratios for these 22 tumors was >2 in 5, <2 and ≥1.7 in 8, and <1.7 in 9. 
Critically none of the diffusely positive cases had an RB1/nuclei ratio of <1. In the 16 ADCs 
with IHC heterogeneity (IHCHet), RB1/nuclei FISH ratios were >2 in 1, <2 and ≥1.7 in 2, and 
<1.7 in 13, of which 5 were <1. Of the 5 ADC with RB1 IHC negative staining (IHCNeg), FISH 
profiles showed 4 cases with an RB1/nuclei ratio <2 and ≥1.7, and one with a ratio of 1.16.  
Of the seven NEPC samples, one had a ratio >2, one <2 and ≥1.7, and 5 had ratios <1.7, of 
which 3 were <1.   All seven NEPCs with available FISH data were RB1 IHCNeg.  
 
Kendall’s Correlation Coefficient was used to determine the association between RB1 
signal/nuclei ratio and H-score. Tumors with an RB1s/nuclei ratio <1.7 were defined as 
having loss; ROC curves with bootstrapped confidence intervals were used to determine an 
optimal cut-off for RB1 H-score to detect cases with a FISH ratio of ≥1.7. The area under the 
ROC curve was 0.55 (95% CI: 0.39-0.74) with an optimal cut-point for H-score of 105 
(Sensitivity 0.77, Specificity 0.25) (Supplementary Figure 3). Overall, these data indicated 
that RB1 copy number losses are common in mCRPCs but did not correlate well with RB1 
IHC protein loss of expression. As demonstrated in the WGS cohort, this was likely due to 
undetected complex structural rearrangements as putative second hits to RB1. 
 
To better understand the relationship between RB1 genomics and protein, we turned to the 
IHC and WGS data of the 21 tumor samples to pursue a detailed characterization of RB1 
loss. For each sample we annotated genomic aberrations with potentially damaging 
functional impact, such as copy number loss, somatic missense SNVs and structural 
rearrangements (tandem duplication and chromosomal translocations) impacting the 
coding region of RB1. These studies showed that RB1 protein expression by IHC correlated 
well with the total number of genomic aberrations detected; the higher the number of 
genomic aberrations at the RB1 locus, the lower the mean RB1 protein level. Specifically, 
tumors carrying no (N=7), one (N=8) or two (N=6) genomic aberrations in RB1 had median 
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IHC scores of 120 (mean=120, SD=35.11), 65 (mean=61.25, SD=57.92) and 0 (mean=0, 
SD=0), respectively (Figure 4). 
 
RB1 expression can be highly heterogeneous in advanced prostate cancer 
Different RB1 IHC staining patterns were observed in mCRPC biopsies (Table 2). Overall, 
homogenous RB1 IHC staining (positive or negative) was seen in 71.7% of the samples 
(76/106). Of these, 56.6% (60/106) of mCRPC biopsies were positive and 15.1% (16/106) 
negative (Figures 5A1-4 and 5B1-4). When categorizing RB1 IHC expression by histological 
phenotype, 61.4% (59/96) of ADCs and one NE cancer (12.5%; 1/8) showed homogeneous 
positivity (Figure 5A4). Complete loss of RB1 expression was seen in 8.3% (8/96) of ADCs 
(Figure 5B1-2) and in 87.5% (7/8) of NE tumors (Figure 5B3-4). Two cases showed mixed 
histology with co-existence of adenocarcinoma and AR-low NEPC. One of these cases with 
had homogenous loss of RB1 IHC expression in both components, whereas the other 
showed positivity in the ADC component and negativity in the NE component in a single 
bone metastases biopsy (Supplementary Figures 5 and 6). Heterogeneous RB1 staining 
patterns were noted in 28% (30/106) of mCRPC samples (see Figure 5C1-4), with most of 
these showing an ADC phenotype (96.6%; 29/30) apart from one sample which had mixed 
histology (Figure 5C4; Supplementary Figure 6). Our data indicate that heterogeneous/focal 
RB1 protein loss of expression is common in mCRPC corroborating reports of loss of RB1 as a 
late event and associated with treatment selective pressures.  
 
Discussion 
CRPC is invariably lethal. However, substantial inter-patient genomic heterogeneity and 
variable sensitivity to established treatments, including endocrine agents and taxane 
chemotherapy lead to variable clinical courses. Robinson et al. suggest that “nearly 90% of 
cases have potentially actionable somatic or germline events” (11). Molecular stratification 
of mCRPC promises to improve the treatment of these diseases (39, 40) but these strategies 
are challenged by intra-patient heterogeneity, which can be difficult to identify from bulk 
exome sequencing. Intra-patient heterogeneity results in mixed responses to anticancer 
drugs; imaging studies, for example, have shown divergent inter-lesion responses to the 
PARP inhibitor olaparib in individual patients with advanced solid tumors (41). Identifying 
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significant intra-patient genomic heterogeneity in mCRPC is thus key to validating 
biomarkers and deliver molecularly stratified treatments.  
 
Herein we obtained whole-genome sequencing of mCRPC tumor biopsies at 100X mean 
coverage and performed focused analyses on somatic variants involving 1,392 cancer 
related genes. In agreement with the data reported by Kumar et al. (15), despite significant 
inter-patient heterogeneity, the majority of somatic genomic aberrations were shared 
between different biopsies of each individual patient at the bulk level. Events involving 
taxonomy defining genes, e.g. ETS fusions, and certain recurrently aberrant tumor 
suppressors such as TP53 mutations and deletions of PTEN, were consistently shared 
between samples from the same patient, in keeping with these being earlier, i.e. prior to 
CRPC state, events (31, 42, 43). Certain cancer-related genes previously reported in prostate 
cancer, however, were identified as private events, favouring later, likely subclonal origins. 
These included: AURKA amplification, mutations in WNT-signalling genes, and RB1 
aberrations. Since TCGA and SU2C/PCF sequencing data suggested an increase in RB1 loss in 
mCRPC compared to primary disease and because of the established role for RB1 loss as a 
predictive biomarker of CDK4/6 inhibitor resistance (35), we pursued a deeper study of RB1 
in a wider cohort of mCRPC biopsies. We found that intra-patient heterogeneity for RB1 loss 
is common in mCRPC both at the genomic and protein levels. Highly relevant for the current 
treatment of mCRPC, we uncover novel complex genomic RB1 structural variants that 
impact RB1 protein expression and that would have gone undetected by exon focused 
sequencing assays. This discovery supports the use of immunohistochemistry, and perhaps 
multiple orthogonal assays, for determining evidence of RB1 loss.  
 
In mCRPC, RB1 inactivation can promote survival benefit via distinct mechanisms including 
an increased output of AR directed transcription (44) or, in combination with inactivation of 
TP53, by inducing a state of plasticity which allows the emergence of AR-low NEPCs (45-47). 
Using WGS, Fraser et al. identified RB1 losses, mono- or biallelic, in 35% of non-indolent 
HSPCs (38), a similar frequency to what we observed in the HSPC samples from our mCRPC 
matched, same-patient, cohort. Furthermore, in agreement with previous studies (5, 9, 11), 
we identify a higher frequency of RB1 loss in mCRPC (56%) than in HSPC (35%). This is 
further evidence that RB1 aberrations, including monoallelic deletions, confer fitness 
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advantages to prostate cancer cells. Critically, in agreement with our data, a study 
evaluating somatic copy number aberrations from WGS data from HSPCs and mCRPC, found 
that partial losses of RB1 are significantly more common than homozygous deletions (48). 
We identified intra-sample heterogeneous loss of RB1 expression by IHC in 28% of our 
mCRPC samples, implicating RB1 depletion as a late and sub-clonal event. We also observed 
an erratic relationship between RB1 IHC protein loss and copy number status as determined 
by FISH. Samples with RB1 mono-allelic deletions showed both homogeneous and 
heterogeneous expression patterns by IHC, and some copy number neutral cases had 
complete absence of protein expression. These data indicate that CN status alone, assessed 
by either massive-parallel sequencing of bulk biopsies or FISH, provides insufficient 
information on RB1 protein expression and function. Even when protein expression is 
present, however, determining RB1 functionality is challenging. Using mRNA derived 
signatures from bulk sequencing has been a recurrent approach (15, 44), but focal RB1 loss-
of-expression/loss-of-function may become diluted in tumors with large proportions of RB1 
functional components.  
 
Our study has limitations. Firstly, our patient cohorts were retrospectively collected and 
heterogeneous in terms of prior treatments with different timing of biopsies in relation to 
treatment lines. This impairs our ability to draw meaningful clinical conclusions regarding 
the prognostic value of the biomarkers we studied. Secondly, we were unable to obtain 
satisfactory RB1 staining from diagnostic HSPC samples. This could be due to different 
factors including tissue block age (several blocks were over a decade old) and the fact that 
these samples were acquired from multiple pathology laboratories with different tissue 
processing protocols. In contrast, our mCRPC samples were, at maximum, up to three years 
old, and were uniformly processed to rigorous protocols. Finally, we did not perform assays 
that could inform on epigenetic silencing of RB1 and thus are unable to assess the 
contribution of methylation events to RB1 inactivation. 
 
In conclusion, previous studies indicate that the proportion of advanced PCas showing 
13q14 (locus of RB1) mono- or bi-allelic deletions ranges from as low as 10% (11) to as high 
as >90% (8) depending on assay used for gene copy number estimation. Herein, we report a 
frequency of RB1 loss by FISH of 56% and intra-sample focal IHC losses of RB1 expression in 
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28% of mCRPCs. Our findings support RB1 aberrations in mCRPCs as resulting from 
treatment selection pressures in most cases. These data are critically important to the study 
of CDK4/6 inhibitors in mCRPC, with such trials now ongoing (e.g. NCT02905318). Overall, 
our data indicate that a significant number of mCRPC have heterogeneous loss of RB1 
protein suggesting CDK4/6 inhibitors may be less efficacious in later stage mCRPC with 
efficacy being limited to patients without RB1 depletion. 
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Figure and Table legends 
 
Figure 1: Landscape of genomic aberrations. Each row represents a gene and each column a 
tumor sample. Specifically, the genomic status (wild type or mutated) is established based 
on the presence or absence of at least one missense somatic point mutation. Grey bars at 
top indicate the fraction of the genome altered by a SCNA event (Copy Number Altered 
Fraction, CNAF) and to the total number of non-synonymous SNVs. Grey bars on the left 
indicate, for each gene, the fraction of samples affected by somatic missense SNV (violet), 
copy number loss (blue) or focal amplification (red). Overall, the total number of non-
synonymous SNVs and CNAFs indicate low intra-patient tumor heterogeneity. Analysis 
focused on a reduced set of known cancer-associated genes revealed heterogeneous 
genomic status for RB1 in patients V5128 and V5033. 
 
Figure 2: Alternative molecular mechanism causing RB1 inactivation in patient V4074. A) 
Paired-end whole genome sequencing data mapped on RB1 locus for 3 metastatic sites of 
patients V4074. Histograms at the top of each alignment track show coverage profiles. Grey 
sequencing reads indicate expected (corrected orientation and insert size of paired reads) 
mapping. Vertical black lines indicate break points detected by BreakDancer algorithm. 
Green highlights pairs of reads with anomalous orientation compatible with a tandem 
duplication event. B) Paired-end RNA sequencing reads from V4074 supporting (green) the 
tandem duplication event involving exons 7 to 17. C) Schematic representation of detected 
tandem duplication. At the top is shown RB1 genomic architecture when tandem 
duplication involving exons 7 to 17 occurs (black boxes). Read pairs with coordinates or 
insert size spanning break points (conjunctions between yellow and black boxes) will 
correctly map (grey reads) in the reference genome (bottom), while read pairs with insert 
size spanning the region between the repeated region (conjunctions between consecutive 
black boxes) will map with anomalous orientation (green reads). D) Left, 
immunohistochemistry of metastatic samples for RB show absence of expression. Right, 
FISH data for RB1 (target probes in red and reference probes in green) support concordantly 
hemizygous loss across all sites. E) Analysis extended to PCF SU2C cohort (N=149) confirms 
that the event is detectable in WES data by ad hoc coverage bases computation. In red, the 
median tumor/normal normalized coverage log-ration profile (y-axis) computed across RB1 
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exons (grouped as indicated on x-axis) for a metastatic site of patient V4074 affected by the 
tandem duplication. Grey lines represent profiles of all other PCF SU2C patients.  
 
Figure 3. RB1 deletion studied by FISH and IHC. A) 20 HSPC-mCRPC paired samples (same 
patient); 35% percent (7/20; 35%) of HSPCs presented at least shallow deletion by our FISH 
definition. In comparison, sixty-five percent (13/20; 65%) of mCRPCs presented at least a 
shallow deletion. Of the 7 patients with HSPCs showing copy number losses by FISH, 6 
presented with copy number lost mCRPC and one case relapsed with a copy number neutral 
mCRPC. Our data shows an enrichment for RB1 deletion in clinically aggressive primary 
prostate cancer. B) X-Y plot of IHC H-Score x RB1 Signal/Nuclei ratio in mCRPCs. A general 
positive correlation is observer between the two variables but several discrepancies exist. 
Our data shows that gene copy number assessed by FISH alone provides insufficient data 
regarding RB1 IHC expression. 
 
Figure 4. Genomic data explains Retinoblastoma protein levels. A) IHC Retinoblastoma 
protein levels against the number of genomic aberrations at RB1 genomic locus with 
potential damaging functional impact. B) Pie chart summarizing RB1 genomic data: the 
external level indicates the number of samples (N=21) carrying none, one or two (yellow, 
orange and red sections, respectively) putative deleterious genomic hits in RB1. Inner level 
specifies the type of RB1 aberrations (light blue, copy number loss; pink, missense SNVs; 
green, structural variant) affecting samples in each previous section. 
 
Figure 5: Micrographs of RB1 IHC staining (200x magnification). Row A) shows examples 
homogeneously positive cases. A range of staining intensities can be appreciated in diffusely 
positive cases. A4) accounts for an AR negative tumor with typical neuroendocrine 
morphology and diffuse positivity for RB1. Row B) shows homogeneously negative cases. 
B1) and B2) are have a typical ADC morphology and were AR positive on IHC. B3) and B4) are 
examples of NEs with confirmed absence of AR staining on IHC. Row C) shows examples of 
RB1 IHC heterogeneous cases. C1), C2), and C3) have an ADC phenotype (confirmed by AR 
IHC). C4) shows one of two cases with RB1 heterogeneous staining pattern and mixed 
histology. 
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Table 1: Summary of clinical data.  
 
  
WGS data + 
RB1 FISH/IHC 
RB1 FISH/IHC 
only 
RB1 IHC  
only 
Total 
 n. Patients 10 30 55 95 
Age 
Median 58.8 61.7 62.99 61.87 
IQR 50.84-61.4 59.04-66.86 57.61-67.39 57.09-66.58 
Staging at 
Diagnosis 
I 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
II 0 (0%) 0 (0%) 3 (5.45%) 4 (4.2%) 
III 4 (40%) 4 (13.33%) 10 (18.18%) 18 (18.94%) 
IV 6 (60%) 22 (73.33%) 33 (60%) 61 (64.21%) 
NA 0 (0%) 4 (13.33%) 9 (16.36%) 13 (13.68%) 
Gleason Score 
GS ≤ 7 4 (40%) 5 (16.66%) 15 (27.27%) 19 (20%) 
GS > 7 5 (50%) 17 (56.66%) 32 (58.18%) 52 (54.73%) 
NA 1 (10%) 8 (26.66%) 8 (14.54%) 17 (17.89%) 
Exposure prior 
to biopsy 
Docetaxel 7 (70%) 20 (66.66%) 36 (65.45%) 63 (66.31%) 
Cabazitaxel 5 (50%) 9 (30%) 14 (25.45%) 28 (29.47%) 
Abiraterone 5 (50%) 23 (76.66%) 38 (69.09%) 66 (69.47%) 
Enzalutamide 4 (40%) 8 (26.67%) 8 (14.54%) 20 (21.05%) 
Carboplatinum 2 (20%) - - - 
 
 
Table 2: Summary of samples, tissue sites of origin, and histology. 
 
   RB1 IHC 
pos
 RB1 IHC 
het
 RB1 IHC 
neg
 
 n. of mCRPC samples 106 (100%) 60 (56.6%) 30 (28.3%) 16 (15.09%) 
Site of 
metastases 
Lymph Node 44 (41.51%) 29 (27.3%) 10 (9.4%) 5 (4.71%) 
Bone 39 (36.79%) 22 (20.75%) 15 (14.15%) 2 (1.88%) 
Visceral 12 (11.32%) 6 (5.66%) 3 (2.83%) 3 (2.8%) 
Soft Tissue 11 (10.38%) 4 (3.77%) 1 (0.0094%) 6 (5.66%) 
Histology 
ADC 96 (90.57%) 59 (55.66%) 29 (27.35%) 8 (7.54%) 
NE 8 (7.55%) 1 (0.0094%) 0 (0%) 7 (6.6%) 
Mixed 2 (1.89%) 0 (0%) 1 (0.0094%) 1 (0.0094%) 
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